Episurf Medical has provided an update on the establishment of its U.S. commercial organization. In line with its strategy for the U.S. market and its first product on the U.S. market, the Episealer Patellofemoral System, Episurf Medical is building a network of third-party distributors.
The company has recently signed agreements with numerous third-party distributors servicing a cumulative population base of nearly 50 million people. Several more agreements are expected to be signed in the coming weeks and months. A group already under agreement collectively distributes for nearly every major orthopedic manufacturer in the industry without a conflicting offering.
For patients with isolated osteoarthritis of the patellofemoral joint, the Episealer Patellofemoral System offers personalized implants on both femur and patella, preserving as much bone as possible by treating only the damaged areas of the joint.
Patrick Jamnik, President of Episurf Medical, said, “Surgeons willingly acknowledge the space within the market where Episurf seeks to fill, as well as the shortcomings of currently available offerings. Paired with the successful clinical history of the Episealer Knee system in Europe, it is clear that our portfolio, present and future, is and will be seen as a welcomed addition to the orthopedic community in the U.S.”
Episurf Medical has provided an update on the establishment of its U.S. commercial organization. In line with its strategy for the U.S. market and its first product on the U.S. market, the Episealer Patellofemoral System, Episurf Medical is building a network of third-party distributors.
The company has recently signed agreements with numerous...
Episurf Medical has provided an update on the establishment of its U.S. commercial organization. In line with its strategy for the U.S. market and its first product on the U.S. market, the Episealer Patellofemoral System, Episurf Medical is building a network of third-party distributors.
The company has recently signed agreements with numerous third-party distributors servicing a cumulative population base of nearly 50 million people. Several more agreements are expected to be signed in the coming weeks and months. A group already under agreement collectively distributes for nearly every major orthopedic manufacturer in the industry without a conflicting offering.
For patients with isolated osteoarthritis of the patellofemoral joint, the Episealer Patellofemoral System offers personalized implants on both femur and patella, preserving as much bone as possible by treating only the damaged areas of the joint.
Patrick Jamnik, President of Episurf Medical, said, “Surgeons willingly acknowledge the space within the market where Episurf seeks to fill, as well as the shortcomings of currently available offerings. Paired with the successful clinical history of the Episealer Knee system in Europe, it is clear that our portfolio, present and future, is and will be seen as a welcomed addition to the orthopedic community in the U.S.”
Copy to clipboard 
